Table 4

Association between CYP17 genotypes and breast cancer risk stratified by selected characteristics

PremenopausalPostmenopausal
A1/A1A1/A2 and A2/A2A1/A1A1/A2 and A2/A2
Case/controlORa (95% CI)Case/controlORa (95% CI)Case/controlORa (95% CI)Case/controlORa (95% CI)
Age at menarche
<13 yr25 /161.024 /291.019 /281.030 /281.0
≥13 yr52 /720.34 (0.15–0.76)62 /860.82 (0.42–1.63)96 /831.49 (0.72–3.10)155 /1350.99 (0.52–1.89)
Postmenopausal use of estrogen
Never86 /691.0134 /941.0
Ever33 /431.14 (0.59–2.18)56 /710.85 (0.51–1.42)
Use of oral contraceptives
Never24 /241.032 /281.092 /761.0164 /1141.0
Ever53 /641.15 (0.49–2.72)54 /870.56 (0.28–1.10)27 /360.82 (0.38–1.77)27 /510.56 (0.29–1.08)
Parity
Nulliparous18 /71.012 /131.027 /151.045 /221.0
Parous59 /810.22 (0.07–0.62)74 /1020.79 (0.31–2.02)95 /970.58 (0.25–1.31)148 /1430.66 (0.35–1.24)
Age at FFTP for parous women
≤23 yr29 /321.031 /451.041 /431.064 /801.0
>24 yr30 /490.83 (0.39–1.79)43 /571.35 (0.69–2.64)54 /540.89 (0.45–1.77)82 /631.45 (0.82–2.59)
BMI
≤25.453 /571.047 /681.045 /451.062 /691.0
>25.424 /300.63 (0.27–1.43)39 /461.03 (0.53–2.01)71 /671.38 (0.70–2.70)123 /951.70 (0.98–2.94)
WHR
<0.9135 /521.036 /611.040 /511.074 /721.0
≥0.9141 /351.66 (0.83–3.34)50 /531.52 (0.83–2.81)79 /601.70 (0.93–3.11)119 /931.13 (0.69–1.85)
  • a Adjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign breast disease, use of oral contraceptives, WHR, and postmenopausal use of estrogen.